STRATEC announces agreement with Abbott Diagnostics
Birkenfeld, December 14, 2010
STRATEC Biomedical Systems AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announced that it has signed an agreement with Abbott Diagnostics, a division of Abbott Laboratories, Abbott Park, Illinois, USA (NYSE: ABT).
The agreement covers the co-development of an analyzer system solution, using STRATEC technology and provides further details about the manufacturing and supply by STRATEC.
Development of the system has already begun as part of a feasibility study. Further project and financial details have not been disclosed.
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999